Injection Pen Market Size, Growth by Product Type (Disposable, Reusable Pens), Therapy (Diabetes (Insulin, GLP-1), Growth Hormone, Osteoporosis, Fertility, Autoimmune disease, Cancer), End User (Hospitals, Clinics, Home Care), and Region - Global Forecasts to 2026
The global injection pen market size is projected to reach USD 53.3 billion by 2026, at a CAGR of 7.2%. Growing prevalence of chronic diseases, increasing number of regulatory approvals, favourable reimbursement and government support, and technological advancements in injection pen tend to drive the market growth. Though the market is growing, but factors like alternative drug delivery modes, poor reimbursement scenarios in developing regions, and needle anxiety tend to restrain the market growth. Whereas, needle-stick injuries & misuse of injection pens tend to pose a challenge for the market. But, the opportunities for the market lie in the patent expiry of biologics and emerging markets.
To know about the assumptions considered for the study, Request for Free Sample Report
Injection Pen Market Dynamics
Driver: Growing prevalence of chronic diseases
The prevalence of chronic diseases has increased significantly in the last few years. Diseases such as diabetes, osteoporosis, cardiovascular disease (CVD), and multiple sclerosis require daily or weekly injectable drug administration. Injector pens are an optimum option for chronic diseases as the frequency of drug administration is high. Injection pens have become the new standard for injectable drug delivery systems. Their popularity has soared due to their simplicity, reliability, and ability to be administered directly by the patient without the aid of a physician. Thus, the growing prevalence of chronic diseases has led to a greater focus on injection pen technologies to effectively handle the growing patient pool and increase patient compliance with therapies. Mentioned below are some key statistics pertaining to the prevalence of chronic diseases.
Restraints: Preference for alternative drug delivery modes
There are many alternatives to injection pen devices. The main restraining factors for injection pens are needle stick anxiety and injury. Hence, there are various needle-free devices that come with an added advantage—they do not induce needle anxiety, which is a significant deterrent to the greater adoption of injectable drug treatments. Non-complacence among children as well as adults is mostly attributed to the pain associated with daily injections and the requirements of long-term therapy. Additionally, insulin pen therapy is seen to cause hyperglycemia in some patients, as the dose cannot be regulated. Hence, in Europe, there has been a shift in diabetes treatment, from insulin pens to insulin pumps, due to their ability to perform automated insulin suspension and decrease the risk of hypoglycemia. In developing countries such as India, China, and Brazil, oral insulin delivery is preferred as it is easy to use, convenient, cost-effective, safe, and acceptable.
Opportunities: Patent expiry of biologics to drive the demand for biosimilars
Biosimilars were introduced in 2006 by many pharmaceutical companies such as Sandoz (Germany), Teva Pharmaceutical Industries Ltd. (Israel), and JCR Pharmaceuticals Co., Ltd. (Japan). Due to their lower costs (as compared to their patented counterparts), the demand for biosimilars has increased significantly. The impending patent expiry of many biologic molecules will also serve to drive the demand for biosimilars. Insurance companies and governments are favoring the use of biosimilars and generics. For instance, CVS Caremark, one of the major prescription insurers in the US, has replaced branded injectable drugs such as Lantus by Sanofi and EpiPen by Mylan with their biosimilars Basaglar (available in injection pen) by Eli Lilly and Adrenaclick (an autoinjector) by Amedra Pharmaceuticals. Since many injectables for the treatment of chronic diseases are biologics, the expiry of patents and growing support from governments and insurance providers provide an opportunity for the growth of the injection pens market.
Challenges: Needle-stick injuries and misuse of injection pens
The lack of proper training and education for the use of new delivery devices such as injection pens leads to improper use and may threaten the safety of the staff and patients. Such practices may affect the adoption of injection pens in a hospital setting. For example, the National Reporting and Learning System (NRLS, UK) reported about 56 incidents associated with withdrawing insulin from insulin pens or refill cartridges between January 2013 and June 2019. In addition, the strength of insulin in the injection pen varies; thus, this poses the risk of overdose if the dose strength is not taken into consideration. The reuse of insulin pens is another concern. According to the Institute for Safe Medication Practices (ISMP) (US), during 2013–2014, ~700 patients in New York may have been exposed to blood-borne pathogens due to the use of insulin pens on multiple patients. The ISMP’s National Medication Errors Reporting Program (MERP) also reported cases where patients forgot to remove the inner cover of a standard insulin pen needle, which resulted in no insulin being delivered. Also, the FDA has reported patients using standard pen needles without removing the inner needle cover. This has resulted in hyperglycemia in patients because the inner needle cover stopped them from getting insulin.
To know about the assumptions considered for the study, download the pdf brochure
North America is expected to account for the largest share of the injection pens market
In 2020, North America dominated the global injection pens market. The large share of the North American injection pens market can primarily be attributed to the rising prevalence of diabetes, favorable reimbursement scenario, and the increasing number of awareness programs.
Prominent players in this market includes Novo Nordisk A/S (Denmark), Becton, Dickinson and Company (US), Ypsomed Holding AG (Switzerland), Sanofi (France), Eli Lilly and Company (US), Merck KGaA (Germany), AstraZeneca plc (UK), F. Hoffmann-La Roche Ltd. (Switzerland), Owen Mumford (UK), Sulzer Ltd. (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Pfizer (US), Biocon Ltd. (India), Lupin Ltd. (India), Wockhardt Ltd. (India), AptarGroup, Inc. (US), Novartis AG (Switzerland), Gerresheimer AG (Germany), Bespak Europe Ltd. (UK), SHL Medical AG (Switzerland), Boehringer Ingelhem (Germany), Nemera France SA, Companion Medical (US), and Jiangsu Delfu Medical Devices Co., Ltd. (China).
Injection Pen Market Scope
Report Metrics |
Details |
Market Size value 2026 |
USD 53.3 billion |
Growth Rate |
7.2% CAGR |
Largest Market |
North America |
Market Dynamics |
Drivers, Opportunities, Restraints & Challenges |
Largest Share Segments |
Disposable injection pens & Diabetes |
Forecasts up to |
2026 |
Market Segmentation |
Product Type, Therapy, End Users and Region |
Injection Pen Market Growth Drivers |
|
Injection Pen Market Growth Opportunities |
|
Report Highlights |
|
Geographies covered |
North America, Europe, APAC, MEA, and Latin America |
The study categorizes the Injection Pen market based on product type, therapy, end user, and regional & global level.
By Product Type
- Disposable Injection Pens
- Reusable Injection Pens
By Therapy
- Diabetes
- Insulin therapy
- GLP-1 therapy
- Growth Hormone
- Osteoporosis
- Fertility
- Auto-immune Diseases
- Cancer
- Other Therapies
By End User
- Home-care Settings
- Hospitals & Diagnostic Clinics
By Region
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Benelux
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Southeast Asia
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Rest of Latin America (RoLA)
- Middle East & Africa
Recent Developments
- In April 2020, Sanofi (France) received FDA approval for a new Dupixent prefilled pen for use in asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyposis for at-home administration.
- In June 2019, Sanofi (France) received approval in Europe for Toujeo SoloStar Pens.
- Merck KGaG (Germany) launched Pergoveris a gonadotropin injection pen for fertility treatment in January 2019.
Frequently Asked Questions (FAQ):
Which are the top industry players in the injection pens market?
The prominent players in the injection pens market are Novo Nordisk A/S (Denmark), Becton, Dickinson and Company (US), Ypsomed Holding AG (Switzerland), Sanofi (France), Eli Lilly and Company (US), Merck KGaA (Germany), AstraZeneca plc (UK), F. Hoffmann-La Roche Ltd. (Switzerland), Owen Mumford (UK), Sulzer Ltd. (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Pfizer (US), Biocon Ltd. (India), Lupin Ltd. (India), Wockhardt Ltd. (India), AptarGroup, Inc. (US), Novartis AG (Switzerland), Gerresheimer AG (Germany), Bespak Europe Ltd. (UK), SHL Medical AG (Switzerland), Boehringer Ingelhem (Germany), Nemera France SA, Companion Medical (US), and Jiangsu Delfu Medical Devices Co., Ltd. (China).
Which geographical region is growing at the largest share in the injection pens market?
In 2020, North America dominated the global injection pens market. The largest share of the North American injection pens market can primarily be attributed to the rising prevalence of diabetes, favorable reimbursement scenario, and the increasing number of awareness programs. The high awareness amongst the patients, increase in the disposable income of the patients and increased adoption of injection pens also contributes to the higher share of the North America in the injection pen market.
Which segment of product type is dominating the injection pens market?
Based on type, the injection pens market is segmented into reusable and disposable injection pens. In 2020, the disposable injection pens segment accounted for the largest share of the global injection pens market. The large share of the disposable injection pens segment can be attributed to their ease of use and the presence of a built-in cartridge which eliminates the need for manually loading the cartridge, making it more convenient for patients with reduced dexterity or visual impairments.
Which is the leading diabetes therapy segment with the largest share in injection pens market?
Based on type of diabetes therapy, the injection pens market for diabetes therapy is segmented into insulin and GLP-1. In 2020, the insulin segment accounted for the highest share of the injection pens market for diabetes therapy. The highest growth of this segment is attributed to factors such as the rising incidence of diabetes across the globe and the high dependence on insulin by diabetes patients.
Which is the highest growing end user segment in injection pens market?
Based on end users, the injection pens market is segmented into home care settings and hospitals & clinics. In 2020, the home care settings segment accounted for the highest growth of the injection pens market. The growing geriatric population, ease of drug administration, increasing prevalence of chronic diseases, technological advancements, and favorable reimbursement scenarios are some of the key factors driving the growth of the home care settings market. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 27)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.3.3 CURRENCY
TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 32)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
2.2 MARKET SIZE ESTIMATION
FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 6 REVENUE SHARE ANALYSIS ILLUSTRATION: SANOFI
FIGURE 7 REVENUE ANALYSIS OF THE TOP FOUR COMPANIES: INJECTION PENS MARKET
FIGURE 8 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE INJECTION PENS MARKET (2021–2026)
FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 10 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 11 MARKET DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS FOR THE STUDY
2.6 RISK ASSESSMENT
TABLE 2 RISK ASSESSMENT: INJECTION PENS MARKET
2.7 LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.7.2 SCOPE-RELATED LIMITATIONS
3 EXECUTIVE SUMMARY (Page No. - 45)
FIGURE 12 INJECTION PEN MARKET, BY TYPE, 2021 VS. 2026
FIGURE 13 INJECTION PEN MARKET, BY THERAPY, 2021 VS. 2026
FIGURE 14 INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE, 2021 VS. 2026
FIGURE 15 INJECTION PEN MARKET, BY END USER, 2021 VS. 2026
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF THE INJECTION PENS MARKET
4 PREMIUM INSIGHTS (Page No. - 49)
4.1 INJECTION PEN MARKET OVERVIEW
FIGURE 17 GROWING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH
4.2 ASIA PACIFIC: INJECTION PEN MARKET, BY THERAPY AND COUNTRY
FIGURE 18 DIABETES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC INJECTION PEN MARKET IN 2020
4.3 INJECTION PEN MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 19 CHINA TO REGISTER THE HIGHEST GROWTH RATE IN THE INJECTION PEN MARKET DURING THE FORECAST PERIOD
4.4 INJECTION PEN MARKET, BY REGION, 2021–2026
FIGURE 20 NORTH AMERICA WILL CONTINUE TO DOMINATE THE GLOBAL INJECTION PEN MARKET IN 2026
4.5 INJECTION PEN MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 53)
5.1 MARKET DYNAMICS
FIGURE 22 INJECTION PEN MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.1.1 MARKET DRIVERS
5.1.1.1 Growing prevalence of chronic diseases
FIGURE 23 NUMBER OF PEOPLE WITH CHRONIC DISEASES IN THE US, 1995–2030 (MILLION INDIVIDUALS)
FIGURE 24 ESTIMATED DIABETIC POPULATION, BY REGION, 2019 VS. 2030 VS. 2040
FIGURE 25 GLOBAL CANCER INCIDENCE, 2015–2040
5.1.1.2 Increasing number of regulatory approvals
5.1.1.3 Favorable reimbursement and government support
5.1.1.4 Technological advancements in injection pens
TABLE 3 MARKET DRIVERS: IMPACT ANALYSIS
5.1.2 MARKET RESTRAINTS
5.1.2.1 Preference for alternative drug delivery modes
5.1.2.2 Poor reimbursement scenario in developing countries
5.1.2.3 Needle anxiety
TABLE 4 MARKET RESTRAINTS: IMPACT ANALYSIS
5.1.3 MARKET OPPORTUNITIES
5.1.3.1 Patent expiry of biologics to drive the demand for biosimilars
5.1.3.2 Growth opportunities in emerging markets
FIGURE 26 DIABETES POPULATION IN DEVELOPING COUNTRIES, 2020 VS. 2040
TABLE 5 RISING INCOME LEVELS IN EMERGING COUNTRIES
TABLE 6 MARKET OPPORTUNITIES: IMPACT ANALYSIS
5.1.4 MARKET CHALLENGES
5.1.4.1 Needlestick injuries and misuse of injection pens
TABLE 7 MARKET CHALLENGES: IMPACT ANALYSIS
5.2 VALUE CHAIN ANALYSIS
FIGURE 27 INJECTION PEN MARKET: VALUE CHAIN ANALYSIS
5.3 SUPPLY CHAIN ANALYSIS
FIGURE 28 INJECTION PEN MARKET: SUPPLY CHAIN ANALYSIS
5.4 PRICING ANALYSIS
TABLE 8 PRICING OF INJECTION PENS AVAILABLE IN THE MARKET
5.5 ECOSYSTEM MARKET MAP
FIGURE 29 INJECTION PEN MARKET: ECOSYSTEM MARKET MAP
5.6 PORTER’S FIVE FORCES ANALYSIS
TABLE 9 INJECTION PEN MARKET: PORTER’S FIVE FORCES ANALYSIS
5.6.1 INTENSITY OF COMPETITIVE RIVALRY
5.6.2 BARGAINING POWER OF SUPPLIERS
5.6.3 BARGAINING POWER OF BUYERS
5.6.4 THREAT OF SUBSTITUTES
5.6.5 THREAT OF NEW ENTRANTS
5.7 REGULATORY ANALYSIS
5.7.1 NORTH AMERICA
5.7.1.1 US
TABLE 10 US FDA: MEDICAL DEVICE CLASSIFICATION
TABLE 11 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
5.7.1.2 Canada
TABLE 12 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
FIGURE 30 CANADA: CLASS II MEDICAL DEVICE APPROVAL PROCESS
5.7.2 EUROPE
FIGURE 31 EUROPE: CE APPROVAL PROCESS FOR CLASS IIA MEDICAL DEVICES
5.7.3 ASIA PACIFIC
5.7.3.1 Japan
TABLE 13 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
5.7.3.2 China
TABLE 14 CHINA: REGULATORY BODIES APPOINTED FOR MEDICAL DEVICE APPROVAL
TABLE 15 CHINA: CLASSIFICATION OF MEDICAL DEVICES
5.7.3.3 India
5.8 IMPACT OF COVID-19 ON THE INJECTION PEN MARKET
5.9 PATENT ANALYSIS
5.9.1 PATENT PUBLICATION TRENDS FOR INJECTION PENS
FIGURE 32 PATENT PUBLICATION TRENDS (JANUARY 2011–SEPTEMBER 2021)
5.9.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
FIGURE 33 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR INJECTION PEN PATENTS (JANUARY 2011–SEPTEMBER 2021)
FIGURE 34 TOP APPLICANT COUNTRIES/REGIONS FOR INJECTION PEN PATENTS (JANUARY 2011–SEPTEMBER 2021)
5.10 TECHNOLOGY ANALYSIS
TABLE 16 PEN INJECTORS CLASSIFICATION
5.10.1 KEY TECHNOLOGIES
5.10.1.1 Dose setting and needle actuation
5.10.1.2 Pen injector material
5.10.2 COMPLEMENTARY TECHNOLOGIES
5.10.2.1 In-built dose and time log
5.10.2.2 Wireless connectivity
5.10.2.3 Smartpen injectors
5.10.2.4 Smart caps and attachments
5.10.2.5 Injector temperature monitoring
5.10.3 ADJACENT TECHNOLOGIES
5.10.3.1 Autoinjectors
5.10.3.2 Insulin pumps
6 INJECTION PENS MARKET, BY TYPE (Page No. - 79)
6.1 INTRODUCTION
TABLE 17 INJECTION PEN MARKET, BY TYPE, 2019–2026
6.2 DISPOSABLE INJECTION PENS
6.2.1 HIGH PATIENT COMPLIANCE AND EASE OF HANDLING TO DRIVE THE ADOPTION OF DISPOSABLE INJECTION PENS
TABLE 18 DISPOSABLE INJECTION PENS AVAILABLE IN THE MARKET
TABLE 19 DISPOSABLE INJECTION PEN MARKET, BY COUNTRY, 2019–2026
6.3 REUSABLE INJECTION PENS
6.3.1 REUSABLE INJECTION PENS TO REGISTER THE HIGHEST GROWTH DUE TO TECHNOLOGICAL ADVANCEMENTS
TABLE 20 REUSABLE INJECTION PENS AVAILABLE IN THE MARKET
TABLE 21 REUSABLE INJECTION PENS MARKET, BY COUNTRY, 2019–2026
7 INJECTION PENS MARKET, BY THERAPY (Page No. - 84)
7.1 INTRODUCTION
TABLE 22 INJECTION PEN MARKET, BY THERAPY, 2019–2026
7.2 DIABETES
TABLE 23 INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 24 INJECTION PEN MARKET FOR DIABETES THERAPY, BY COUNTRY, 2019–2026
7.2.1 INSULIN
7.2.1.1 Rising prevalence of diabetes is driving the growth of this market
TABLE 25 EXAMPLES OF INSULIN INJECTION PENS
TABLE 26 INJECTION PEN MARKET FOR INSULIN THERAPY, BY COUNTRY, 2019–2026
7.2.2 GLUCAGON-LIKE PEPTIDE-1 (GLP-1) THERAPY
7.2.2.1 Strong focus of major pharmaceutical companies to introduce GLP-1 drugs to drive market growth
TABLE 27 EXAMPLES OF GLP-1 INJECTION PENS
TABLE 28 INJECTION PEN MARKET FOR GLP-1 THERAPY, BY COUNTRY, 2019–2026
7.3 GROWTH HORMONE THERAPY
7.3.1 DEVELOPMENT OF SUSTAINED-RELEASE GROWTH HORMONE FORMULATIONS FOR REDUCING INJECTION FREQUENCY TO RESTRAIN THE MARKET GROWTH
TABLE 29 EXAMPLES OF INJECTION PENS FOR GROWTH HORMONE THERAPY
TABLE 30 INJECTION PEN MARKET FOR GROWTH HORMONE THERAPY, BY COUNTRY, 2019–2026
7.4 OSTEOPOROSIS
7.4.1 GROWING PREVALENCE OF OSTEOPOROSIS IN GERIATRIC PATIENTS AND WOMEN TO DRIVE MARKET GROWTH
TABLE 31 EXAMPLES OF INJECTION PENS FOR OSTEOPOROSIS THERAPY
TABLE 32 INJECTION PEN MARKET FOR OSTEOPOROSIS THERAPY, BY COUNTRY, 2019–2026
7.5 FERTILITY
7.5.1 DECREASE IN FERTILITY RATE HAS RESULTED IN THE INCREASED USE OF INJECTION PENS
TABLE 33 EXAMPLES OF INJECTION PENS FOR FERTILITY THERAPY
TABLE 34 INJECTION PEN MARKET FOR FERTILITY THERAPY, BY COUNTRY, 2019–2026
7.6 CANCER
7.6.1 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH
TABLE 35 EXAMPLES OF INJECTION PENS FOR CANCER THERAPY
TABLE 36 INJECTION PEN MARKET FOR CANCER THERAPY, BY COUNTRY, 2019–2026
7.7 AUTOIMMUNE DISEASES
7.7.1 DEVELOPMENTS IN THERAPIES AND DELIVERY DEVICES FOR THE TREATMENT OF MS TO BOOST THE MARKET GROWTH
TABLE 37 EXAMPLES OF INJECTION PENS FOR MULTIPLE SCLEROSIS AND PSORIASIS THERAPY
TABLE 38 INJECTION PEN MARKET FOR AUTOIMMUNE DISEASE THERAPY, BY COUNTRY, 2019–2026
7.8 OTHER THERAPIES
TABLE 39 INJECTION PEN MARKET FOR OTHER THERAPIES, BY COUNTRY, 2019–2026
8 INJECTION PENS MARKET, BY END USER (Page No. - 100)
8.1 INTRODUCTION
TABLE 40 INJECTION PEN MARKET, BY END USER, 2019–2026
8.2 HOME CARE SETTINGS
8.2.1 HOME CARE SETTINGS ARE THE LARGEST END USERS OF INJECTION PENS
TABLE 41 INJECTION PEN MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2019–2026
8.3 HOSPITALS & CLINICS
8.3.1 GROWING INCIDENCE OF NEEDLESTICK INJURIES AND UNSAFE INJECTION PRACTICES HAVE INCREASED THE DEMAND FOR INJECTION PENS
TABLE 42 INJECTION PEN MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2019–2026
9 INJECTION PENS MARKET, BY REGION (Page No. - 105)
9.1 INTRODUCTION
TABLE 43 INJECTION PENS MARKET, BY REGION, 2019–2026
FIGURE 35 EMERGING COUNTRIES ARE EXPECTED TO WITNESS HIGHER GROWTH IN THE FORECAST PERIOD
9.2 NORTH AMERICA
FIGURE 36 NORTH AMERICA: INJECTION PENS MARKET SNAPSHOT
TABLE 44 INJECTION PENS MARKET, BY COUNTRY, 2019–2026
TABLE 45 NORTH AMERICA: INJECTION PENS MARKET, BY TYPE, 2019–2026
TABLE 46 NORTH AMERICA: INJECTION PENS MARKET, BY THERAPY, 2019–2026
TABLE 47 NORTH AMERICA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 48 NORTH AMERICA: INJECTION PENS MARKET, BY END USER, 2019–2026
9.2.1 US
9.2.1.1 The US dominates the North American injection pens market
FIGURE 37 TOTAL FERTILITY RATE IN THE US POPULATION (1990-2020)
TABLE 49 US: KEY MACROINDICATORS
TABLE 50 US: INJECTION PENS MARKET, BY TYPE, 2019–2026
TABLE 51 US: INJECTION PENS MARKET, BY THERAPY, 2019–2026
TABLE 52 US: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 53 US: INJECTION PENS MARKET, BY END USER, 2019–2026
9.2.2 CANADA
9.2.2.1 Unfavorable regulatory processes in Canada to restrain the market growth
TABLE 54 CANADA: KEY MACROINDICATORS
TABLE 55 CANADA: INJECTION PENS MARKET, BY TYPE, 2019–2026
TABLE 56 CANADA: INJECTION PENS MARKET, BY THERAPY, 2019–2026
TABLE 57 CANADA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 58 CANADA: INJECTION PENS MARKET, BY END USER, 2019–2026
9.3 EUROPE
TABLE 59 EUROPE: INJECTION PENS MARKET, BY COUNTRY, 2019–2026
TABLE 60 EUROPE: INJECTION PENS MARKET, BY TYPE, 2019–2026
TABLE 61 EUROPE: INJECTION PENS MARKET, BY THERAPY, 2019–2026
TABLE 62 EUROPE: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 63 EUROPE: INJECTION PENS MARKET, BY END USER, 2019–2026
9.3.1 GERMANY
9.3.1.1 High diabetes expenditure and reimbursement for injection pens to drive the market in Germany
TABLE 64 GERMANY: KEY MACROINDICATORS
TABLE 65 GERMANY: INJECTION PENS MARKET, BY TYPE, 2019–2026
TABLE 66 GERMANY: INJECTION PENS MARKET, BY THERAPY, 2019–2026
TABLE 67 GERMANY: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 68 GERMANY: INJECTION PENS MARKET, BY END USER, 2019–2026
9.3.2 FRANCE
9.3.2.1 Misuse of injection pens pose a threat to the growth of this market
TABLE 69 FRANCE: KEY MACROINDICATORS
TABLE 70 FRANCE: INJECTION PENS MARKET, BY TYPE, 2019–2026
TABLE 71 FRANCE: INJECTION PENS MARKET, BY THERAPY, 2019–2026
TABLE 72 FRANCE: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 73 FRANCE: INJECTION PENS MARKET, BY END USER, 2019–2026
9.3.3 UK
9.3.3.1 NHS support and access to cost-effective injection pens are likely to drive the market in the UK
TABLE 74 UK: KEY MACROINDICATORS
TABLE 75 UK: INJECTION PENS MARKET, BY TYPE, 2019–2026
TABLE 76 UK: INJECTION PENS MARKET, BY THERAPY, 2019–2026
TABLE 77 UK: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 78 UK: INJECTION PENS MARKET, BY END USER, 2019–2026
9.3.4 ITALY
9.3.4.1 Regional variation in terms of coverage and benefits to hinder the market growth
TABLE 79 ITALY: KEY MACROINDICATORS
TABLE 80 ITALY: INJECTION PENS MARKET, BY TYPE, 2019–2026
TABLE 81 ITALY: INJECTION PENS MARKET, BY THERAPY, 2019–2026
TABLE 82 ITALY: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 83 ITALY: INJECTION PENS MARKET, BY END USER, 2019–2026
9.3.5 SPAIN
9.3.5.1 Supportive regulations mandating the use of safety injection pens to boost the growth of the Spanish market
TABLE 84 SPAIN: KEY MACROINDICATORS
TABLE 85 SPAIN: INJECTION PENS MARKET, BY TYPE, 2019–2026
TABLE 86 SPAIN: INJECTION PENS MARKET, BY THERAPY, 2019–2026
TABLE 87 SPAIN: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 88 SPAIN: INJECTION PENS MARKET, BY END USER, 2019–2026
9.3.6 BENELUX
9.3.6.1 Increasing awareness about injection pen devices to drive market growth
TABLE 89 BENELUX: INJECTION PENS MARKET, BY TYPE, 2019–2026
TABLE 90 BENELUX: INJECTION PENS MARKET, BY THERAPY, 2019–2026
TABLE 91 BENELUX: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 92 BENELUX: INJECTION PENS MARKET, BY END USER, 2019–2026
9.3.7 REST OF EUROPE
TABLE 93 ROE: INJECTION PENS MARKET, BY TYPE, 2019–2026
TABLE 94 ROE: INJECTION PENS MARKET, BY THERAPY, 2019–2026
TABLE 95 ROE: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 96 ROE: INJECTION PENS MARKET, BY END USER, 2019–2026
9.4 ASIA PACIFIC
FIGURE 38 ASIA PACIFIC: INJECTION PENS MARKET SNAPSHOT
TABLE 97 APAC: INJECTION PENS MARKET, BY COUNTRY, 2019–2026
TABLE 98 APAC: INJECTION PENS MARKET, BY TYPE, 2019–2026
TABLE 99 APAC: INJECTION PENS MARKET, BY THERAPY, 2019–2026
TABLE 100 APAC: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 101 APAC: INJECTION PENS MARKET, BY END USER, 2019–2026
9.4.1 JAPAN
9.4.1.1 High diabetes incidence and supportive reimbursement policies to drive the market growth in Japan
TABLE 102 JAPAN: KEY MACROINDICATORS
TABLE 103 JAPAN: INJECTION PENS MARKET, BY TYPE, 2019–2026
TABLE 104 JAPAN: INJECTION PENS MARKET, BY THERAPY, 2019–2026
TABLE 105 JAPAN: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 106 JAPAN: INJECTION PENS MARKET, BY END USER, 2019–2026
9.4.2 CHINA
9.4.2.1 Large patient population and healthcare infrastructure improvements to drive the market growth in China
TABLE 107 CHINA: KEY MACROINDICATORS
TABLE 108 CHINA: INJECTION PENS MARKET, BY TYPE, 2019–2026
TABLE 109 CHINA: INJECTION PENS MARKET, BY THERAPY, 2019–2026
TABLE 110 CHINA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 111 CHINA: INJECTION PENS MARKET, BY END USER, 2019–2026
9.4.3 INDIA
9.4.3.1 Rising prevalence of obesity to drive market growth
TABLE 112 INDIA: KEY MACROINDICATORS
TABLE 113 INDIA: INJECTION PENS MARKET, BY TYPE, 2019–2026
TABLE 114 INDIA: INJECTION PENS MARKET, BY THERAPY, 2019–2026
TABLE 115 INDIA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 116 INDIA: INJECTION PENS MARKET, BY END USER, 2019–2026
9.4.4 SOUTHEAST ASIA
9.4.4.1 Growing awareness about diabetes to drive the adoption of injection pens
FIGURE 39 DIABETES PREVALENCE IN SOUTHEAST ASIA (2019)
FIGURE 40 HEALTHCARE EXPENDITURE (% OF GDP) IN SOUTHEAST ASIA (2018)
FIGURE 41 GERIATRIC POPULATION (% OF THE TOTAL POPULATION), 2019
TABLE 117 SOUTHEAST ASIA: INJECTION PENS MARKET, BY TYPE, 2019–2026
TABLE 118 SOUTHEAST ASIA: INJECTION PENS MARKET, BY THERAPY, 2019–2026
TABLE 119 SOUTHEAST ASIA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 120 SOUTHEAST ASIA: INJECTION PENS MARKET, BY END USER, 2019–2026
9.4.5 REST OF APAC
TABLE 121 ROAPAC: INJECTION PENS MARKET, BY TYPE, 2019–2026
TABLE 122 ROAPAC: INJECTION PENS MARKET, BY THERAPY, 2019–2026
TABLE 123 ROAPAC: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 124 ROAPAC: INJECTION PENS MARKET, BY END USER, 2019–2026
9.5 LATIN AMERICA
TABLE 125 LATAM: INJECTION PENS MARKET, BY COUNTRY, 2019–2026
TABLE 126 LATAM: INJECTION PENS MARKET, BY TYPE, 2019–2026
TABLE 127 LATAM: INJECTION PENS MARKET, BY THERAPY, 2019–2026
TABLE 128 LATAM: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 129 LATAM: INJECTION PENS MARKET, BY END USER, 2019–2026
9.5.1 BRAZIL
9.5.1.1 Brazil dominates the injection pens market in Latin America
TABLE 130 BRAZIL: KEY MACROINDICATORS
TABLE 131 BRAZIL: INJECTION PENS MARKET, BY TYPE, 2019–2026
TABLE 132 BRAZIL: INJECTION PENS MARKET, BY THERAPY, 2019–2026
TABLE 133 BRAZIL: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 134 BRAZIL: INJECTION PENS MARKET, BY END USER, 2019–2026
9.5.2 MEXICO
9.5.2.1 Increasing incidence of lifestyle-related disorders to drive market growth in Mexico
TABLE 135 MEXICO: KEY MACROINDICATORS
TABLE 136 MEXICO: INJECTION PENS MARKET, BY TYPE, 2019–2026
TABLE 137 MEXICO: INJECTION PENS MARKET, BY THERAPY, 2019–2026
TABLE 138 MEXICO: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 139 MEXICO: INJECTION PENS MARKET, BY END USER, 2019–2026
9.5.3 REST OF LATIN AMERICA
FIGURE 42 HEALTH EXPENDITURE (% OF GDP) IN LATIN AMERICAN COUNTRIES, 2018
TABLE 140 ROLATAM: INJECTION PENS MARKET, BY TYPE, 2019–2026
TABLE 141 ROLATAM: INJECTION PENS MARKET, BY THERAPY, 2019–2026
TABLE 142 ROLATAM: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 143 ROLATAM: INJECTION PENS MARKET, BY END USER, 2019–2026
9.6 MIDDLE EAST & AFRICA
9.6.1 INITIATIVES TO ENHANCE HEALTHCARE ACCESSIBILITY TO SUPPORT MARKET GROWTH
TABLE 144 MEA: INJECTION PENS MARKET, BY TYPE, 2019–2026
TABLE 145 MEA: INJECTION PENS MARKET, BY THERAPY, 2019–2026
TABLE 146 MEA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026
TABLE 147 MEA: INJECTION PENS MARKET, BY END USER, 2019–2026
10 COMPETITIVE LANDSCAPE (Page No. - 162)
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES
10.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
FIGURE 43 REVENUE ANALYSIS OF THE TOP PLAYERS IN THE INJECTION PENS MARKET
10.4 MARKET SHARE ANALYSIS
FIGURE 44 INJECTION PENS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
10.5 MARKET RANKING ANALYSIS OF OEM COMPANIES
FIGURE 45 INJECTION PENS MARKET RANKING, BY OEM COMPANY
10.6 COMPANY EVALUATION QUADRANT
10.6.1 STARS
10.6.2 EMERGING LEADERS
10.6.3 PERVASIVE PLAYERS
10.6.4 PARTICIPANTS
FIGURE 46 INJECTION PENS MARKET: COMPANY EVALUATION QUADRANT
10.7 COMPANY EVALUATION QUADRANT FOR START-UPS
10.7.1 PROGRESSIVE COMPANIES
10.7.2 DYNAMIC COMPANIES
10.7.3 STARTING BLOCKS
10.7.4 RESPONSIVE COMPANIES
FIGURE 47 INJECTION PENS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS
10.8 COMPANY PRODUCT FOOTPRINT
TABLE 148 PRODUCT PORTFOLIO ANALYSIS: INJECTION PENS MARKET, BY TYPE
TABLE 149 PRODUCT PORTFOLIO ANALYSIS: INJECTION PENS MARKET, BY THERAPY
10.9 GEOGRAPHIC FOOTPRINT OF MAJOR PLAYERS IN THE INJECTION PENS MARKET
TABLE 150 GEOGRAPHIC REVENUE MIX: INJECTION PENS MARKET
10.10 COMPETITIVE SCENARIO
10.10.1 PRODUCT LAUNCHES
TABLE 151 PRODUCT LAUNCHES (JANUARY 2018–SEPTEMBER 2021)
10.10.2 OTHER DEVELOPMENTS
TABLE 152 OTHER DEVELOPMENTS (JANUARY 2018–SEPTEMBER 2021)
11 COMPANY PROFILES (Page No. - 176)
11.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View)*
11.1.1 NOVO NORDISK A/S
TABLE 153 NOVO NORDISK A/S: BUSINESS OVERVIEW
FIGURE 48 NOVO NORDISK A/S: COMPANY SNAPSHOT
11.1.2 BECTON, DICKINSON AND COMPANY
TABLE 154 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 49 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
11.1.3 YPSOMED HOLDING AG
TABLE 155 YPSOMED HOLDING AG: BUSINESS OVERVIEW
FIGURE 50 YPSOMED HOLDING AG: COMPANY SNAPSHOT
11.1.4 SANOFI
TABLE 156 SANOFI: BUSINESS OVERVIEW
FIGURE 51 SANOFI: COMPANY SNAPSHOT
11.1.5 ELI LILLY AND COMPANY
TABLE 157 ELI LILLY AND COMPANY: BUSINESS OVERVIEW
FIGURE 52 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
11.1.6 MERCK KGAA
TABLE 158 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 53 MERCK KGAA: COMPANY SNAPSHOT
11.1.7 ASTRAZENECA
TABLE 159 ASTRAZENECA: BUSINESS OVERVIEW
FIGURE 54 ASTRAZENECA: COMPANY SNAPSHOT
11.1.8 F. HOFFMANN-LA ROCHE LTD.
TABLE 160 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 55 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
11.1.9 OWEN MUMFORD
TABLE 161 OWEN MUMFORD: BUSINESS OVERVIEW
11.1.10 SULZER LTD.
TABLE 162 SULZER LTD.: BUSINESS OVERVIEW
11.1.11 SUN PHARMACEUTICAL INDUSTRIES LTD.
TABLE 163 SUN PHARMACEUTICAL INDUSTRIES LTD: BUSINESS OVERVIEW
FIGURE 56 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
11.1.12 PFIZER
TABLE 164 PFIZER: BUSINESS OVERVIEW
FIGURE 57 PFIZER: COMPANY SNAPSHOT
11.1.13 BIOCON LTD.
TABLE 165 BIOCON LTD.: BUSINESS OVERVIEW
FIGURE 58 BIOCON LTD.: COMPANY SNAPSHOT
11.1.14 LUPIN LTD.
TABLE 166 LUPIN LTD.: BUSINESS OVERVIEW
FIGURE 59 LUPIN LTD.: COMPANY SNAPSHOT
11.1.15 WOCKHARDT LTD.
TABLE 167 WOCKHARDT LTD.: BUSINESS OVERVIEW
FIGURE 60 WOCKHARDT LTD.: COMPANY SNAPSHOT
11.1.16 APTARGROUP, INC.
TABLE 168 APTARGROUP, INC.: BUSINESS OVERVIEW
FIGURE 61 APTARGROUP, INC.: COMPANY SNAPSHOT
11.1.17 NOVARTIS AG
TABLE 169 NOVARTIS AG: BUSINESS OVERVIEW
FIGURE 62 NOVARTIS AG: COMPANY SNAPSHOT
11.1.18 GERRESHEIMER AG
TABLE 170 GERRESHEIMER AG: BUSINESS OVERVIEW
FIGURE 63 GERRESHEIMER AG: COMPANY SNAPSHOT
11.2 OTHER PLAYERS
11.2.1 SHAILY ENGINEERING PLASTICS LTD.
TABLE 171 SHAILY ENGINEERING PLASTICS LTD.: BUSINESS OVERVIEW
11.2.2 BESPAK EUROPE LTD.
TABLE 172 BESPAK EUROPE LTD.: BUSINESS OVERVIEW
11.2.3 SHL MEDICAL AG
TABLE 173 SHL MEDICAL AG: BUSINESS OVERVIEW
11.2.4 EMPERRA GMBH
TABLE 174 EMPERRA GMBH: BUSINESS OVERVIEW
11.2.5 NEMERA FRANCE SAS
TABLE 175 NEMERA FRANCE SAS: BUSINESS OVERVIEW
11.2.6 COMPANION MEDICAL, INC.
TABLE 176 COMPANION MEDICAL, INC.: BUSINESS OVERVIEW
11.2.7 JIANGSU DELFU MEDICAL DEVICE CO., LTD.
TABLE 177 JIANGSU DELFU MEDICAL DEVICE CO., LTD.: BUSINESS OVERVIEW
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
12 APPENDIX (Page No. - 223)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
Secondary Research
This research study involved the usage of comprehensive secondary sources; directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the injection pen market. It was also used to obtain important information about the key players, market classification and segmentation according to industry trends to the bottommost level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side and demand side are detailed below.
A breakdown of the primary respondents is provided below:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the injection pen market was arrived at after data triangulation from two different approaches, as mentioned below. After each approach, the weighted average of all approaches was taken based on the level of assumptions used in each approach.
Data Triangulation
After arriving at the market size, the total market was divided into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics for all segments and sub-segments, data triangulation and market breakdown procedures were employed, wherever applicable. The following figure shows the market validation, source structure, and data triangulation methodology implemented in this report’s market engineering process.
Objectives of the Study
- To validate the segmentation defined through the assessment of the product portfolios of the leading players in the market
- To understand key industry trends and issues defining the growth objectives of market players
- To gather both demand- and supply-side validation of the key factors affecting market growth, including market drivers, restraints, opportunities, and challenges
- To validate assumptions for the market sizing and forecasting model used for this market study
- To understand the market positions of the leading players in the injection pen market and their shares/rankings
- To understand the ongoing pricing trends in the market and future expectations
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
Geographic Analysis
- Further breakdown of the RoE injection pens market into Russia, Switzerland, Denmark, Austria, and others
- Further breakdown of the RoAPAC injection pens market into South Korea, Taiwan, and others
- Further breakdown of the RoLATAM injection pens market into Argentina, Colombia, Chile, Ecuador, and others
- Further breakdown of the Southeast Asia injection pens market into Malaysia, Singapore, Australia, New Zealand, and others
Competitive Landscape Assessment
- Market share analysis, by region (North America and Europe), which provides market shares of the top 3-5 key players in the injection pen market
- Competitive leadership mapping for established players for the US
Growth opportunities and latent adjacency in Injection Pen Market
who are the prominent players in diabetes injection pens market. pls share list
Need tailor made research report on injection pen market with informative data and various critical aspects such as market outlook, market share, growth, and trends.
advancements in injection pen market. how is it going to sustain. details pls